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Sincethe pioneering workofKunkel et al. (1, 2), a number ofstudies established
that human monoclonal IgM with a defined antibody activity such as rheumatoid
factors (RF)t or cold agglutinins (CA) share crossreactive idiotopes (CRI).
In sharpcontrast, ithasbeen exceedinglydifficulttoobtain antiidiotypic reagents
defining CRI onhuman monoclonal IgM reactive with myelin-associated glycopro-
tein (MAG). Whereas most studies yielded reagents that only defined private idio-
topes on the immunizing IgM (3-6), we and others have previously shown that a
restricted set ofanti-MAG IgM shared CRI defined by asmall subset ofantibodies
from rabbit andidiotypic sera (7) or by mouse mAbs (8). The lack ofbroadly dis-
tributed CRI is not related to an heterogeneity ofthe fine specificity ofthese IgM
since several studies indicate that most if not all react with a glucuronyl sulfated
epitope carriedbyMAGand aperipheral nerve glycolipid, the sulfated 3-glucuronyl
paragloboside (SGPG) (9, 10).
We report here the characterization, by a primate serum to human anti-MAG
IgM, ofcombining site-related idiotope(s) shared by 9 of 10 IgM, and the assign-
ment oflight and heavychains of7 ofthese IgM to Igvariable subgroups as defined
by their NH2-terminal amino acid sequence.




Serawere obtained from 10 patients with monoclonal IgMand
peripheral neuropathy. The specificity ofthemonoclonal IgM was assessed by immunoblot-
tinganalysis on human central nervous system myelin polypeptides. For some experiments,
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ANTIGENIC AND STRUCTURAL FEATURES OF ANTIMYELIN IgM
MAG was prepared from delipidated myelin by lithium diodosalicylate and phenol extrac-
tion according to Quarles and Pasnak (11).
Partial NH2Terminal Sequence of IgM Heavy and Light Chains.
￿
Monoclonal IgM were iso-
lated from sera by 40% saturated ammonium sulfate precipitation and were purified by gel
chromatography followed by preparative zone electrophoresis. IgA, IgG, haptoglobin, and
transferrin contaminants were removed on affinity adsorbents. Heavy and light chains were
obtained by mild reduction performed with 10 mM 1-4 dithio-Dl-threitol and alkylation with
10% excess of [ 14G]iodoacetic acid (7.5. 106 cpm/mol) (Amersham Corp., Amersham, UK);
thereafter the chains were separated on a Sephadex Gloo column equilibrated with 1 M acetic
acid. The typing of variable regions from heavy and light chains was achieved by Edman
sequence degradation, using 4N,N'-dimethylarninoazobenzene-4'isothiocyanate (Fluka, Buchs,
Switzerland)/phenyl-isothiocyanate (Pierce Chemical Co., Rockford, IL) double-coupling
method followed by thin-layer chromatography (12).
Antiidiotypic Serum.
￿
An adult marmoset was injected with purified IgMROG; the first im-
munization was performed subcutaneously in IFA (500 Ag IgM in multiple sites) and booster
injections were given every 15 d with IgMRor, resuspended in saline buffer. Bleedings were
obtained at monthy intervals and tested by double immunodiffusion against a panel ofmono-
clonal anti-MAG IgM and normal serum. Bleedings that reacted strongly with anti-MAG
IgM but not or weakly with normal serum were pooled and absorbed on Sepharose 4B beads
coupled to normal human serum, polyclonal IgG, or four different monoclonal IgM devoid
ofanti-MAG specificity. This marmoset antiidiotypic serum was thereafterstudied by ELISA.
ELISAAssays.
￿
The reactivity ofmarmoset antiidiotypic serum with anti-MAG or normal
IgM was assessed by two ELISA assays. First, microtiter plates (Consortium de Materiel
pour Laboratoire, Nemours, France) coated with 1 Ag IgM/well for 18 h were blocked with
3 % BSA in saline and incubated with serial dilutions of marmoset antiidiotypic serum; the
binding ofmarmoset IgG was revealed with S-galactosidase-labeled goat antibodies to human
IgG (Biosys, Compiegne, France) followed by substrate. No reactivity was recorded when
the addition of marmoset antiidiotypic was omitted or when nonimmune marmoset serum
was used. A similar assay was performed on plates coated with 10 l~g/well of purified A, K,
or X chains.
Alternatively, monoclonal IgM were incubated for 12 h on plates precoated with 1 wg/well
of mouse mAb to t~ heavy chain. Thereafter, marmoset antiidiotypic antibody was added
at a 10-1 dilution and the assay was developed with phosphatase alkaline-conjugated purified
goat IgG to human (and primate) .y chains (Caltag Laboratory, San Francisco, CA) absorbed
on mouse Ig, followed by substrate.
Inhibition experiments were performed as follows: anti-A precoated plates were incubated
with 5 Rg/well IgMDEp and revealed by marmoset antiidiotypic antibody (1/30 final dilution)
previously incubated for 12 h with various amounts (10-2 to 102 l~g) of anti-MAG or of an
irrelevant monoclonal IgM followed by phosphatase alkaline-conjugated purified goat anti-
bodies to human y chains and substrate.
In other experiments, glutaraldehyde-pretreated plates were incubated with 10 Ag ofpurified
MAG, blocked with L-lysine and various amounts of anti-MAG IgM previously incubated
for 18 h with a 1/50 final dilution of marmoset antiidiotypic serum were added. Plates were
revealed with a-galactosidase-labeled goat antibodies to human l~ chains followed by sub-
strate (Biosys).
Results
Specificity ofMarmoset Antiidiotypic Serum. As evidenced by immunoblotting ex-
periments, the 10 IgM studied reacted with 90/100-kD polypeptides of myelin corre-
sponding to MAG. In addition, IgM bound to purified MAG by immunoblotting
or ELISA assays (not shown).
As shown in Fig. 1, 9 of 10 anti-MAG IgM reacted with marmoset antiidiotypic
serum in two different assays. The immunizing IgMRoG always yielded the highest
optical densities, whereas IgMLoc gave only background values similar to that ob-c 1.4
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Reactivity of marmoset antiidiotypic serum with 10 anti-MAG IgM (closed symbols),
irrelevant IgM (open symbols), or isolated heavy and light chains in ELISA. (A) Direct binding
using serial dilutions of marmoset antiidiotypic serum. (B) IgM were captured on anti-,u-coated
plates before addition of a 10-1 dilution of marmoset antiidiotypic serum (See Methods).
served with irrelevant monoclonal IgM. Inhibition studies confirmed the existence
ofcrossidiotopes between IgM (Fig. 2 A) since the fixation of marmoset antiidio-
typic serum to IgMDEP (i.e., an IgM different from that used for immunization)
was completely inhibitedin thepresence ofanti-MAG IgMstudiedbutwas unaffected
by an irrelevant IgMLEC.
At least some ofthe shared idiotopes appeared to be related to the combining
site of the IgM since incubation of four IgM with marmoset antiidiotypic serum
inhibitedtheirbindingto MAGbyELISA (Fig. 2 B). In similarexperiments, rabbit
antiserato anti-MAG IgM that recognized privateor semipublic idiotopes were not
inhibitory (7; and unpublished data).
Marmoset antiidiotypic serum did not react either with isolated heavy and light
chains from the six anti-MAG IgMtested orwith variablesubgroup matched'uchains
or purified light chains (Fig. 1 B). Finally, various marmoset bleedings were tested
by fluorescence on nerve sections for the presence of anti-antiidiotypic (ab3) anti-
bodies: nonewere found, even inlatebleedings aftertheendofboosterimmunizations.
NH2Terminal Sequence of Heavy and Light Chairs ofAnti-MAG IgM.
￿
Ofseven IgM
studied, only one possessed X chains (AZI) with a Vxtt variable region. Three K
chains (DEP, FUE, and LOC) belonged to the VKIV subgroup with characteristic
amino acids at position 9 and 12 (13). Two K chains (BOU and BLA) were assigned
to the V,,l subgroup, although several mutations existed in comparison to proto-
type sequence (Table I) since they had the relatively invariant amino acids ofVKI
subgroupatposition 3 and 13 andnoneofthecharacteristic amino acids ofthe other
subgroups. Finally, IgM PEC belonged to the VK1I subgroup as shown by its NH2-
terminal sequence and the finding ofan invariant methionine atposition 89. Heavy
chain NH2-terminal amino acid sequence allowed the assignment to the VH111 sub-
group of 6 p. chains whose 10 first residues were identical to that of the VHIII Gal
prototype sequence (13). IgM AZI belonged to the VHII subgroup with a single1554
￿
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FIGURE 2 .
￿
Shared idiotype(s) between anti-MAG IgM are combining site-related . (A) Anti-
MAG IgMROG,DEP YSE, eau, pEc, but not irrelevant IgM, inhibit the binding of marmoset
antiidiotypic serum to I9MDEP-coated plates (See Materials and Methods) . (B) Inhibition of
binding of various concentrations of IgMRoG (5), DEP (" ), Rou (A), PEC (t) to MAG-coated
plates by a 1/50 dilution ofmarmoset antiidiotypic serum. Closed symbols represent optical den-




NH2-Terminal Sequence of seven Anti-MAG IgM Light Chains Compared
with that of Prototype Sequence of Variability Subgroups
' Amino acids are designated by the single letter code. Only deviations from
the prototype are shown.
amino acid substitution at position 7 (threonine for serine) when compared with
the OU prototype sequence.
Discussion
Monoclonal IgMdirected to MAGand nerve glycolipids recently attracted much
interest since they may mediatethe first instance ofhuman autoimmune peripheral
neuropathy. Although this matter remains controversial, intraneural injections of
anti-MAG IgMaswell aspassive transfer experimentssupportthispossibility(reviewed
in reference 14). So far theantigenic and biochemical features ofthese IgM remain
poorly characterized.
We show herethat a primate antiserum tohuman anti-MAG IgM contains anti-
bodies to a combiningsite-related public crossidiotype carriedby 9of 10 IgMtested.
This antiserumwasable toblockthebindingofmonoclonal IgMto MAG and reacted
with several IgM having K or X chains and 1A heavy chain belonging to VHIII (all
IgM tc) or VHII (one IgM X) subgroups. In addition, inhibition studies suggested
that all reactive IgM share a similar set ofidiotopes. This marmoset antiidiotypic
serum most likely recognizes conformational epitope(s) sinceit was unreactive with
isolated light andheavychains. Theseresultscontrastwith thosefrom previous reports
where onlyprivate orhighly restricted idiotypes were disclosed by rabbit polyclonal
antisera and mouse mAbs antibodies (3-8; and unpublished data). The reasons for
thisdiscrepancyare not readily apparent. Ofnote, mouse and rabbit MAG areun-
reactive with human anti-MAG IgM and possibly the repertoire of these animals
is submitted to idiotypec regulationdependingon the structure ofselfantigens. Such
species-restricted ab2 responsehave alreadybeen observed forRF(15). Onthe other
hand, structural data (see below) showed that the combining site of these IgM is
most often composed ofVHIII-related heavy chains paired with Kchains belonging
to different subgroups ofvariability. Therefore, epitopes exposed at the surface of
the IgM and that areimmunogeneic inthesespeciesmay bedifferent from one IgM
Sequence'
Protein 1 2 3 4 5 6 7 8 9 10 11 12 13
VKt SCW D I Q M T Q S P S S L S A
IgM BOU - - - - - - - - T T - T -
IgM BLA - - - - - - - - T T - - -
VKn TEW D I V M T Q S P L S L P V
IgM PEC - V - - - - - - V T - - -
VKIV LEN D I V M T Q S P N S L A V
IgM DEP - - - - - E - - E - - - -
IgM FUE - - - - - E - - - - - - -
IgM LOG - - - - - - - - - - - - -
Vats NEI PCA S A L T Q P A S V S G S
IgM AZI L - - - - - - P - - T - -1556
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to the other. In either instance, more related species, such as nonhuman primates,
couldmoreeasily recognizehumananti-MAGIgM combining sites.Thatsuchbroadly
crossreactive antiidiotypic antibodies are mostly directed against epitope(s) involved
in (or close to) the combining site is not unexpected in view ofthe highly restricted
specificity of anti-MAG IgM for a glucuronyl sulfated epitope ofthe carbohydrate
moiety ofMAG andperipheralnerve glycolipid SGPG (9, 10). However, slight differ-
ences in the fine specificity ofanti-MAG IgM may exist(16, 17), and could account
for thevariable levels ofbinding to marmoset antiidiotypic serum ofdifferent anti-
MAG IgM.
Dissection ofthe antigenic and structural relationship between individual mono-
clonal RF or CA in humans revealed that only a limited number ofgermline genes
undergoing relatively few somatic mutations contribute to the generation ofthese
monoclonal antibodies(18-20). Strikingly, a majority ofmonoclonalRForCA possess
light chains belonging to the VHIII subgroup. Most of them derive from a single
(Hum 325) or closely related variable K genes. Since other autoantibodies use also
VKHIb-related genes (21), a model for autoantibody generation has been proposed
wherethebindingspecificity is definedbythevariablesegmentofheavy chains paired
with multipotential light chains (18). Obviously anti-MAG IgM do not fit within
this scheme; light chains from these IgM indeed belong to different VK variability
subgroups (VKI, VKII, VKIv) and none are related to the Von subgroup so far. In-
terestingly half ofthe K chains studied belong to the rare VKIv subgroup, which is
associated with <5% ofsequenced light chains and coded by a single germline VKIv
gene.
These various light chains of anti-MAG were associated in all but one instance
to VHIII-derived IL heavy chains. Such a restriction ofheavy chain variable regions
is consistent with previous data forboth RF and CA. However, atleastthreedifferent
VHI variable genes are used by the RF belonging to the Wa CRI group and limited
structural studies showed that salient features were the use of a JH4 region and of
DH regions of uniform size (22). Therefore, more structural data are needed to at-
tain meaningful conclusions.
Altogether thepresent resultsindicatethatanti-MAG IgM exhibitdistinct antigenic
andstructural features as comparedwiththoseofothermonoclonal IgMwith adefined
antibody activity. Whetheror not they correspond to different pathogenetic processes
(antigen-driven autoantibodies versus spontaneous production of autoantibodies
from germline genes with few somatic mutations) presently remains speculative.
Summary
Most studiesusing rabbit ormouse antisera failed to detect CRI between human
IgM directed to MAG. We show here that 9 of 10 such IgM express a public CRI
as defined by a nonhuman primate antiserum. Shared idiotype is likely involved
in (orcloseto) the combining site of those IgM since antiidiotypic serum inhibited
thebinding ofIgM to MAG andreactedwith IgMhaving differentvariable regions
oflightand heavychains. Partial aminoterminal sequence ofheavy andlightchains
showed that anti-MAG IgM use either X chains (one IgM) or K light chains (six
IgM) ofdifferent variability subgroups (VKIv in three instances, VKI in two, and VKII
in one), whereas heavy chains belong to the VHIII (six IgM) or to the VHII (1 IgM)BROUET ET AL.
￿
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subgroup. These features distinguish these IgM from other human monoclonal IgM
with a defined antibody activity, such as rheumatoid factors or cold agglutinins.
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